Type Public Industry Pharmaceuticals Website www.titanpharm.com Number of employees 13 (June 2015) | Traded as NASDAQ: TTNP Key people Sunil Bhonsle Founded 1992 | |
 | ||
Stock price TTNP (NASDAQ) US$ 3.30 -0.10 (-2.94%)31 Mar, 4:00 PM GMT-4 - Disclaimer Headquarters South San Francisco, California, United States Profiles | ||
ttnp titan pharmaceuticals inc independent analysis 6 24 16
Titan Pharmaceuticals, Inc. is a California biopharmaceutical company developing proprietary therapeutics primarily for the treatment of central nervous system ("CNS") disorders.
Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine hydrochloride ("buprenorphine") for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016.
References
Titan Pharmaceuticals Wikipedia(Text) CC BY-SA